FIELD: medicine. invention relates to
SUBSTANCE: new thrombomoduline fusion proteins providing directional transfer to tissue factor useful as anticoagulants. In particular disclosed is anticoagulating fusion protein which is operably bonded to thrombomoduline (TM) EGF456 domain and TM domain including interdomain loop between EGF3 and EGF4, derivatives or variants and interacting with tissue factor (TF) or VIIa/TF factor complex. Fusion protein is bonded in damage site and prevents thrombosis initiation and is useful in therapy of various thrombosis conditions, including but not limited deep vein thrombosis, consumption coagulopathy, and acute coronary syndrome.
EFFECT: agent with enhanced applications.
24 cl, 8 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
| MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USE THEREOF | 2007 |
|
RU2492184C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| FUSED PROTEIN, HAVING FACTOR VII ACTIVITY | 2011 |
|
RU2585231C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| BIVALENT BISPECIFIC ANTIBODIES | 2008 |
|
RU2587616C2 |
| ANTIBODY AGAINST THE CELL ADHESION MOLECULE L1 OR ITS ANTIGEN-BINDING FRAGMENT AND CHIMERIC ANTIGEN RECEPTOR CONTAINING IT | 2019 |
|
RU2789360C2 |
| METHOD OF SCREENING GAMMA-SECRETASE INHIBITORS | 2004 |
|
RU2373284C2 |
